Updates are available Correction dated 2021-07-01
Click to view Correction: https://doi.org/10.1186/s12879-021-06333-y
-
Authors
Trombetta, Bianca A.
Kandigian, Savannah E.
Kitchen, Robert R.
Grauwet, Korneel
Webb, Pia Kivisäkk
Miller, Glenn A.
Jennings, Charles G.
Jain, Sejal
Miller, Samara
Kuo, Yikai
Sweeney, Thadryan
Gilboa, Tal
Norman, Maia
Simmons, Daimon P.
Ramirez, Christopher E.
Bedard, Melissa
Fink, Catherine
Ko, Jina
De León Peralta, Esmarline J.
Watts, Gerald
Gomez-Rivas, Emma
Davis, Vannessa
Barilla, Rocky M.
Wang, Jianing
Cunin, Pierre
Bates, Samuel
Morrison-Smith, Chevaun
Nicholson, Benjamin
Wong, Edmond
El-Mufti, Leena
Kann, Michael
Bolling, Anna
Fortin, Brooke
Ventresca, Hayden
Zhou, Wen
Pardo, Santiago
Kwock, Megan
Hazra, Aditi
Cheng, Leo
Ahmad, Q. Rushdy
Toombs, James A.
Larson, Rebecca
Pleskow, Haley
Luo, Nell Meosky
Samaha, Christina
Pandya, Unnati M.
De Silva, Pushpamali
Zhou, Sally
Ganhadeiro, Zakary
Yohannes, Sara
Gay, Rakeisha
Slavik, Jacqueline
Mukerji, Shibani S.
Jarolim, Petr
Walt, David R.
Carlyle, Becky C.
Ritterhouse, Lauren L.
Suliman, Sara
- License Information
-
More Information
Article History
Received: 8 February 2021
Accepted: 25 May 2021
First Online: 16 June 2021
Declarations
:
: All samples were collected from participants who provided informed consent. Sample and data collection conformed to Good Clinical Practice guidelines and Declaration of Helsinki. The study was approved under the Massachusetts General Brigham (MGB) Institutional Review Board (protocol no. 2020P001204).
: Not applicable.
: DRW has a financial interest in Quanterix Corporation, a company that develops an ultra-sensitive digital immunoassay platform. He is an inventor of the Simoa technology and a founder of the company and also serves on its Board of Directors. DRW's interests were reviewed and are managed by Brigham and Womens Hospital and Partners HealthCare in accordance with their policies on competing interests. The assays in this publication have been licensed by Brigham and Womens Hospital to Quanterix Corporation. MN, TG and DRW have filed intellectual property on the technology described in this manuscript.All other authors did not declare a conflict of interest.
